Remarkable bone formation following gefitinib for extensive lytic bone metastasis: a report of two cases

J Orthop Surg (Hong Kong). 2016 Dec;24(3):421-423. doi: 10.1177/1602400330.

Abstract

Gefitinib inhibits the epidermal growth factor receptor tyrosine kinase and improves survival in patients with non-small-cell lung cancer. We report 2 patients with extensive lytic bony metastasis in the spine and pelvis secondary to advanced pulmonary adenocarcinoma who were treated with gefitinib and had remarkable bone formation in the lytic bone lesions in the spine and pelvis. Surgery for stabilisation was avoided.

Keywords: adenocarcinoma of lung; bone cysts; gefitinib; neoplasm metastasis; receptor, epidermal growth factor.

Publication types

  • Case Reports

MeSH terms

  • Adenocarcinoma / drug therapy*
  • Adenocarcinoma / secondary*
  • Adenocarcinoma of Lung
  • Aged, 80 and over
  • Antineoplastic Agents / therapeutic use*
  • Bone Neoplasms / secondary*
  • Female
  • Gefitinib
  • Humans
  • Lung Neoplasms / drug therapy*
  • Lung Neoplasms / secondary*
  • Male
  • Middle Aged
  • Osteogenesis / drug effects*
  • Pelvic Bones / pathology
  • Quinazolines / therapeutic use*
  • Spine / pathology

Substances

  • Antineoplastic Agents
  • Quinazolines
  • Gefitinib